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TrueNAT MTBTo evaluate the performance of TrueNAT (RT Micro PCR device) assay in comparison with
GeneXpert on sputum samples from pulmonary cases of tuberculosis. 274 samples were
processed to detect MTB by ZN smear examination, MGIT culture and molecular methods
that included RT-PCR (ABI 7500 & TrueNAT) and GeneXpert for case detection of TB. The
overall performance of the test with MGIT(Mycobacterium Growth Indicator Tube) culture
as gold standard, sensitivity of smear, RT PCR/TrueNAT and Genexpert was 61.5% (CI:53.3–
69.3%), 94.7% (CI:89.8–97.6%) & 96.0% (CI: 91.5–98.5%), respectively. Amongst the S+ (108)
samples, RT-PCR/TrueNAT and GeneXpert showed a sensitivity of 99% (CI:94.9%–99.8%)
and 100% (98.6%–100.0%), respectively. High concordance was observed between GeneXpert
and TrueNAT for case detection of TB. The GeneXpert MTB/RIF test was independent on the
user’s skills. It has a short turn-around time and simultaneously detects RIF resistance with
M. tuberculosis in less than 3 h. The TrueNAT MTB has good sensitivity and specificity in
case detection with hands on time of less than 3 h as well as fits the requirements in
resourcelimited health care settings. Larger, multi-site studies are required to obtain better
estimates of the performance of TrueNAT MTB.
 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Background
Diagnosis of tuberculosis (TB) in the developing world
presents an urgent need for novel solutions. Despite effective
anti-TB medication, TB continues to contribute to the large
death toll caused by curable infectious diseases. The global
annual incidence estimates about 8.8 million cases, of which
1.5 million cases are from India [1]. Since 2007, the World
Health Organization (WHO) has approved many newdiagnostic tests for TB [2,3]. However, smear microscopy,
which has varying sensitivity [4] and under-reports a large
number of early stage cases, is still the most widely used test
in the developing world.
The commercially available automated, liquid MGIT
(Mycobacterium Growth Indicator tube) culture system is
time-consuming and requires specialized laboratories. Molec-
ular tests such as polymerase chain reaction (PCR), though
sensitive, still take time as specimens are often sent to distantrkar Marg,
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in PCR testing establishes a barrier to implementation in most
of the TB-endemic countries. Quick and affordable diagnoses
are critical to prevent TB-related casualties.
There has been substantial interest in developing cost-
effective molecular tests that can be used ‘‘near-patient’’ as
a means to curb the TB menace. With combined advantages
of affordability, ease of use, diagnostic sensitivity and porta-
bility, low-cost, point-of-care molecular devices that enhance
the efforts to treat diseases before they spread and cause irre-
versible damage to the patient’s health are good candidates
for wide-scale use among the peripheral laboratories in India
and other countries of South-East Asia, which accounts for
50% of the global burden of TB.
A recent example of the developments in the field of TB
diagnostics is the GeneXpert system (Cepheid, Sunnyvale,
CA), an automated real-time PCR system that simultaneously
detects both Mycobacterium tuberculosis complex (MTBC) and
Rifampicin (RIF) resistance in less than 2 h. Recent studies
reported high sensitivity and specificity of the Xpert MTB/
RIF test in the detection of TB from respiratory specimens
[5–9], collected from patients living in countries with both
high and low prevalence of TB. GeneXpert is endorsed by
the WHO for use in national TB control programs. In endemic
countries, the use of the Xpert MTB/RIF is often limited to lab-
oratories with a controlled environment [10,11].
There is an urgent need for cost-effective molecular tests
that can be used as point-of-care to curb the TB menace. Tests
that can be used in ‘‘low-infrastructure’’ settings could save
thousands of lives that are otherwise lost to TB every year
[12]. Bigtec Laboratories, Bangalore, India has developed a bat-
tery-operated, portable micro PCR device, the TrueNAT MTB,
RT-PCR micro device, as well as Trueprep MAG for extraction
of DNA directly from samples for early detection of TB.
In a pilot study [13], it was reported that a novel TB test,
the TrueNAT MTB, was able to detect TB rapidly with good
sensitivity in comparison with a Composite Reference
Standard (CRS). The test, TrueNAT (Fig. 1), offered faster and
accurate results as compared with in-house nested PCRFig. 1 – TrueNAT micro PCR device for chip-based real-time
PCR.protocol. Using a CRS as the benchmark, a sensitivity and
specificity of 91.1% and 100%, respectively, was reported for
TrueNAT. In the current study, its performance was assessed
against the widely accepted and WHO approved GeneXpert
MTB/RIF for case detection of TB.
Methods
Ethics
This study was approved by the Institutional Review Board
(IRB). Waiver of consent was obtained by the IRB, as the study
was carried out on left-over banked specimens identified by a
laboratory generated number with no traceability to the
patients. The TrueNAT MTB/GeneXpert results were not used
in clinical decision making.
Settings
Sample collection, Smear Microscopy, MGIT culture and
GeneXpert was performed at Hinduja Hospital and Medical
Research Centre, Mumbai. The TB lab is accredited with the
College of American Pathologist (CAP), National Accreditation
Board for Laboratories (NABL) and Central TB Division,
Governmet of India (CTD, GOI) for liquid culture and DST. It
is the referral laboratory for TB. Real-time PCR and TrueNAT
MTB tests were performed by trained Hinduja hospital staff
at Bigtec Labs, Bangalore.
Study population and specimens
This was a blinded study to determine the performance of the
TrueNAT in patients with symptoms of pulmonary TB in com-
parison with conventional methodologies (smear and culture)
and GeneXpert. Sputum specimens were collected from
patients presenting routinely to hospital with suspected pul-
monary TB. Standard diagnostic follow-up (smear, culture,
GeneXpert) was performed on all patients. Left-over sputum
specimens were tested using TrueNAT. A total of 274
(n = 274) sputum samples were collected from patients sus-
pected of having TB (Fig. 3).
Laboratory work-up of sputum specimens
Ziehl Neelsen (ZN) smear: Direct and concentrated acid-fast
bacillus (AFB) microscopy (ZN staining) was performed and
specimens were graded as per WHO recommended criteria,
followed by sputum processing with 2% N-acetyl-L-cysteine
and sodium hydroxide (NALC–NaOH) and centrifugation
[14,15]. The re-suspended pellet was subjected to cultivation
on liquid medium MGIT, supplied by Becton Dickinson.
Digested and decontaminated (2% NALC–NaOH) sputum
specimens that were culture negative for mycobacterium
and confirmed ‘‘Non-TB’’ by sequencing were pooled for use
as a negative control. A suspension of M. tuberculosis H37RV
was prepared in sterile saline and adjusted to the density of
a 1.0 McFarland standard. The suspension was diluted 1:10
in saline and used to spike the pooled above-mentioned neg-
ative control and used as a positive control. Spiked specimens
were stored at 70 C until further processing.
274 specimens were screened 
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Fig. 3 – Flow diagram of study selection.
Sensitivity
0 0.2 0.4 0.6 0.8 1
SMEAR 0.54    (0.47 - 0.61)
CULTURE 0.70    (0.63 - 0.76)
TRUENAT 0.97    (0.93 - 0.99)
Sensitivity (95% CI)
Pooled Sensitivity = 0.74 (0.70 to 0.77)
Chi-square = 113.08; df =  2 (p = 0.0000)
Inconsistency (I-square) = 98.2 %
Fig. 2 – Forest plot for sensitivity values of Smear, Culture, and True NAT (microbiological and molecular methods) with
pooled sensitivity as compared with GeneXpert. Performance of molecular methods studies reporting sensitivity. Point
estimates of sensitivity estimates from each study are shown as solid circles. Solid lines represent the 95%CI (CI = confidence
interval).
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DNA extraction using Trueprep-MAG protocol
Untreated sputum specimens were processed as per
manufacturer’s instructions of Trueprep-MAG Sputum kit
with a starting volume of 500 ll being added to the sample
pre-treatment tube [13].Real-time PCR on chip
5 ll of DNA extracted added to the TrueNAT MTB microchip
containing lyophilized mastermix and the real-time PCR
was done using a pre-programmed profile on the device.
Results were observed on the screen. The lyophilized master-
mix included proprietary primers and a probe specific to the
M. tuberculosis.
Table 1 – Performance (% of cases detected) of molecular tests in various specimen categories.
Test S+ C+ S+C+ SC+
(n = 108) (n = 151) (n = 93) (n = 58)
Xpert MTB/RIF 100 96.02 100 90.14
[96.5–100.00] [89.09–98.63] [96.5–100.00] [88.71–94.35]
TrueNAT MTB 99.07 92.71 98.92 86.21
[94.2–99.95] [88.65–97.06] [94.2–99.95] [74.07–93.44]
Table 2 – Comparison of TrueNAT MTB with Xpert MTB/RIF results.
(n = 274) GeneXpert
Positive Negative
TrueNAT MTB Positive 198 3
Negative 8 65
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PCR reactions were run using the DNA extracted using the
Trueprep-MAG protocol. 4 ll of extracted DNA was mixed with
6 ll of the TrueNAT MTB mastermix and real-time PCR was
performed on real-time PCR (Applied Biosystems) under the
following cycling conditions: 1 min at 95 C and 45 cycles of
10 s at 95 C and 34 s at 58 C.
Buffers, reagents and mastermixes
All buffers and reagents used for nucleic acid extraction and
all mastermixes used for PCR are proprietary constituents of
the Trueprep-MAG Sputum and TrueNAT MTB kit.
Xpert MTB/RIF
The assay was performed as per the manufacturer’s instruc-
tions [5].
Statistical analysis
Evaluation of the TrueNAT MTB test was performed in com-
parison with the other molecular methods for detection of
Mycobacterium tuberculosis DNA from sputum, following the
STARD recommendations [16]. Sensitivity, Specificity, Positive
Predictive Value, and Negative Predictive Value, were calcu-
lated by using the http://www.vassarstats.net/ and MedCalc
software online clinical calculator.
Results
Evaluation of TrueNAT MTB was performed using the Xpert
MTB/RIF as a benchmark, another well standardized molecu-
lar method. A total of 274 samples were screened, the Xpert
MTB/RIF assay was repeated for 17 samples (9 had Error
messages and 8 were Invalid). After repeating, 4 samples were
still invalid, hence excluded from the study. Of the 4 invalid
samples, 1 was S+C+, and the remaining 3 were SC. The
inhibition rate of GeneXpert was 6.2% (17/274). Out of 274
samples, as shown in the flow chart (Fig. 3), 93/274 were
S+C+, 58/274 were SC+, 15/274 were S+C and 108/274 wereSC; 108/274 were smear positive (S+), 151/274 were culture
positive (C+), 93/274 were smear and culture positive (S+C+).
Among the 166/274 smear negative (S) cases, 58 were culture
positive (SC+).
In S+C+ category, Xpert detected 93 (100%) samples,
whereas TrueNAT MTB and RT-PCR (Applied Biology) detected
92 (98.9%) samples as MTB. In SC+ category, Xpert detected
52 (90.1%) of 58 samples, whereas TrueNAT MTB detected 50
(86.8%) and RT-PCR (Applied Biology) detected 51 (87.9%) of
58 samples as MTB, as shown in Table 1.
Among the S+ (108) samples, TrueNAT MTB and GeneXpert
detected 99.0% (CI: 94.9–99.8%) and 100% (96.5–100.00%) of
sensitivity respectively. In the overall performance of the test
keeping GeneXpert as the standard, the sensitivity of smear,
culture and RT PCR/TrueNAT is as shown in Table 3 and
Figure 2.
Sensitivity and specificity for smear-positive pulmonary
samples is much higher as compared with the overall sensi-
tivity for the remaining tests. GeneXpert and TrueNAT
showed good sensitivity for S+ pulmonary samples. These
sensitivities are analogous to previous studies [5,17].
The TrueNAT MTB results (which were run on both the
TrueNAT micro PCR device and the RT-PCR) were largely
concordant with Xpert MTB/RIF results (Tables 1 and 2).
Out of 247 samples, 229 samples (92.7%) showed identical
results (detected or undetected) for both the Xpert MTB/
RIF and TrueNAT MTB systems. Of the 18 discordant results,
3 samples were positive by TrueNAT MTB, but negative by
Xpert MTB/RIF. On the other hand, 8 samples were positive
by GeneXpert, but negative by TrueNAT MTB. Of this group,
all samples were SC. The TrueNAT MTB assay had a
higher sensitivity when compared with conventional
methodologies.
Discussion
In the current study, TrueNAT assay showed a high concor-
dance with the GeneXpert system. Thus, the system might
be a potential, accurate and rapid method for detecting TB
cases in high TB burden countries like India.
Table 3 – Sensitivity, specificity, of TrueNAT MTB and GeneXpert MTB/RIF with smear and culture method as reference with
test performance of TrueNATwith GeneXpert. All the figures are in %. Figures in the brackets indicate 95% confidence interval.
Test Performance MGIT culture GeneXpert ABI/TRUENAT
Vs smear
Sensitivity 86.11% (78.13–92.01%) 100% (96.61–100%) 100% (96.61–100%)
Specificity 65.06% (57.29–72.28%) 40.96% (33.40–48.85%) 43.98% (36.29–51.88%)
Vs culture
Test Performance Smear GeneXpert ABI/TRUENAT
Sensitivity 61.59% (53.33–69.38%) 96.03% (91.55–98.52%) 94.70% (89.82–97.68%)
Specificity 87.80% (80.68–93.01%) 50.41% (41.25–59.54%) 52.85 % (43.64–61.91%)
Test Performance GeneXpert vs TrueNAT
Sensitivity 96.12% (92.49–98.30%)
Specificity 95.59% (87.63–99.03%)
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standard–can detect very low concentrations of organisms.
However, the current liquid and solid culture systems take
several weeks to yield results. Also, the testing process
requires sophisticated laboratory and specifically trained per-
sonnel. These technologies are therefore suited to centralized
laboratories and are not suitable for use in peripheral set-
tings. Although molecular amplification is already a proven
technology in TB diagnosis, existing testing methods are not
applicable in most of the TB endemic countries due to lack
of an adequate healthcare infrastructure.
In a previous study, TrueNAT assay with culture and CRS as
the gold standard was evaluated. While this is the most con-
venient reference method [18,19], the platform, which has
been rolled out in various endemic countries, could poten-
tially lead to millions of disability adjusted life years (DALYs)
saved as faster treatment in response to a quicker diagnosis
would ensure that the transmission of the disease is cur-
tailed. However, the Xpert MTB/RIF requires a continuous
supply of electricity to maintain a controlled environment
to perform the test and hence, is not practical in near-patient
settings. Patients/samples are still required to travel to the
nearest testing center. This limits its use in peripheral
settings and in active case finding (ACF) programs [18]. In
routine practice, the MTB/RIF test is much faster (3–24 h) than
culture, which requires 3–6 weeks. The sensitivity of the
TrueNAT MTB is much higher than smear microscopy or
culture (Table 3).
With the TrueNAT MTB test, specimens can be tested as
soon as a patient presents with symptoms. The entire set-
up, being battery operated and portable, can be deployed at
the lower levels of the healthcare pyramid. This can help in
reducing the logistical hurdles involved with transporting
sputum specimens to distant referral laboratories. The turn-
around time between collection of sample and diagnosis of
TB could be greatly reduced as well. Processing a single sam-
ple on each device decreases the cross-contamination issues.
As a portable platform, it could also be utilized in ACF pro-
grams, which are the current need of the hour to improve
detection rates and reduce the incidence of infection. There
is a great need for rapid, accurate diagnostic products for
early diagnosis of TB in low-prevalence and high-prevalence
areas to prevent the spread of TB.A limitation of TrueNAT MTB is that it cannot determine
MDR-TB, which is of most significance in high burden coun-
tries like India. But, as compared with any other molecular
method, it is very cost effective.
In conclusion, the GeneXpert MTB/RIF assay is indepen-
dent of the user’s skills, and routine staff with minimal train-
ing can use the test. It has a shorter turnaround time and
simultaneously detects RIF resistance in less than 3 h. The
TrueNAT MTB test has good sensitivity and specificity for case
detection of TB as compared with Xpert with hands-on time
less than 3 h. However, larger, multi-site studies are required
to obtain better estimates of the performance of TrueNAT
MTB.Conflict of interest
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